1-7 of 7
Ying Ou
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Exposure-Response Relationship of the Bruton Tyrosine Kinase Inhibitor, Zanubrutinib (BGB-3111) in Patients with Hematologic Malignancies

Ying Ou, PhD, Kun Wang, PhD, Lucy Liu, MBA, Ashutosh Jindal, BS, Yuying Gao, PhD, Sri Sahasranaman, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5063.
https://doi.org/10.1182/blood-2019-129580
Published: 2019
Journal Articles

A Quantitative Systems Pharmacology (QSP) Model to Predict Receptor Occupancy of Bruton's Tyrosine Kinase (BTK) Inhibitors in Peripheral Blood Mononuclear Cells, Bone Marrow and Lymph Nodes of Patients with B-Cell Malignancies

Srikumar Sahasranaman, PhD, Oleg Demin, Jr., Dmitry Shchelokov, Veronika Musatova, Nageshwar Budha, PhD, Ying Ou, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1289.
https://doi.org/10.1182/blood-2019-129133
Published: 2019
Journal Articles

An Open-Label, Single-Arm, Phase 1 Study of the Pharmacokinetics (PK) and Safety of Carfilzomib in Patients with Relapsed Multiple Myeloma and End-Stage Renal Disease (ESRD)

Hang Quach, MBBS (Hons), FRACP, FRCPA, MD, Darrell White, Andrew Spencer, P. Joy Ho, Divaya Bhutani, Mike White, Sandeep Inamdar, Chris Morris, Ying Ou, Martin Gyger
Journal: Blood
Blood (2016) 128 (22): 3318.
https://doi.org/10.1182/blood.V128.22.3318.3318
Published: 2016
Journal Articles

A Phase 1 Study Evaluating Pharmacokinetics (PK) and Safety of Carfilzomib in Patients with Advanced Malignancies and Varying Degrees of Hepatic Impairment (HI)

Jennifer Brown, Ruth Plummer, Stephen Anthony, John Sarantopoulos, Filip De Vos, Mike White, Marco Schupp, Ying Ou, Ulka Vaishampayan
Journal: Blood
Blood (2016) 128 (22): 4496.
https://doi.org/10.1182/blood.V128.22.4496.4496
Published: 2016
Journal Articles

CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma

Clinical Trials & Observations
James R. Berenson, Alan Cartmell, Alberto Bessudo, Roger M. Lyons, Wael Harb, Dimitrios Tzachanis, Richy Agajanian, Ralph Boccia, Morton Coleman, Robert A. Moss, Robert M. Rifkin, Priti Patel, Sandra Dixon, Ying Ou, Janet Anderl, Sanjay Aggarwal, Jesus G. Berdeja
Journal: Blood
Blood (2016) 127 (26): 3360–3368.
https://doi.org/10.1182/blood-2015-11-683854
Published: 2016
Includes: Supplemental data
Journal Articles

Weekly Carfilzomib with Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Updated Results from the Phase 1/2 Study Champion-1 (NCT01677858)

James Berenson, MD, Alan Cartmell, Roger Lyons, Wael Harb, Dimitrios Tzachanis, Richy Agajanian, Ralph V. Boccia, MD, Morton Coleman, Robert A. Moss, MD, Robert M. Rifkin, Marco Schupp, Sandra Dixon, Ying Ou, Janet Anderl, Jesus G. Berdeja, MD
Journal: Blood
Blood (2015) 126 (23): 373.
https://doi.org/10.1182/blood.V126.23.373.373
Published: 2015
Journal Articles

A Phase 1, Dose-Escalation Study (CHAMPION-1) Investigating Weekly Carfilzomib In Combination With Dexamethasone For Patients With Relapsed Or Refractory Multiple Myeloma

James R. Berenson, MD, Leonard Klein, MD, Robert M. Rifkin, MD, Priti Patel, MD, MS, Sandra Dixon, MS, Ying Ou, PhD, Alan Cartmell, MD
Journal: Blood
Blood (2013) 122 (21): 1934.
https://doi.org/10.1182/blood.V122.21.1934.1934
Published: 2013